



**World Health  
Organization**

# **Follow-Up: Filoviruses research meeting**

**Strategic agenda for Filoviruses research and  
monitoring (AFIRM)**

**Tuesday, 17 May 2022**

**(14:00-16:00 CET)**

## **Draft Agenda**



**R&DBlueprint**

Powering research  
to prevent epidemics

## Objectives of the meeting

The aim of this meeting is to continue discussing the research priorities for filovirus diseases.

These priorities will be embedded in three major action areas, namely:

**ANTICIPATION:** Research Strategies to prevent and control future Filovirus outbreaks.

**REINFORCEMENT:** Research strategies to develop and evaluate additional vaccines.

**CURE:** Foster research to improve standard of care and the development and evaluation of treatments and of post-exposure therapies.

Time	Topic	Speakers
<b>Main Room</b> <b>Zoom link:</b> <a href="https://who-e.zoom.us/meeting/register/tJUtd-GoqTMjHdSTTBu1-k3ft7XfZSxXuN2i">https://who-e.zoom.us/meeting/register/tJUtd-GoqTMjHdSTTBu1-k3ft7XfZSxXuN2i</a> <b>Password: AFIRM</b>		
14:00 – 14:10	<b>Welcome &amp; Objectives of the meeting</b> <b>Anticipation:</b> Challenges in filovirus diagnostics and surveillance	César Muñoz-Fontela (BNITM/WHO)
14:10 – 14:20	<b>Reinforcement:</b> Outlook of filovirus vaccine research	William Dowling (WHO, CEPI)
14:20 – 14:30	<b>Cure:</b> Standardization of medical care for filoviral diseases	Simon Funnell (WHO, UKHSA)
<b>Breakout Rooms</b>		
14:30 – 15:30	<b>Anticipation</b> <ol style="list-style-type: none"> <li>What data needs to be collected for prevention of future outbreaks? What kind of analysis models and co-operations do we need to analyze such data?</li> <li>Would it be worthwhile to setup a web-based filovirus surveillance database?</li> <li>Do we have the right diagnostic tools? If not, what tools need to be implemented?</li> <li>What tools do we have in place to prevent relapse and initiation of outbreaks via transmission from survivors?</li> <li>What is the role of domestic animal and wildlife surveillance for outbreak prevention? What is the best strategy?</li> </ol>	<b>Chairs</b> César Muñoz-Fontela (BNITM/WHO) William Dowling (WHO, CEPI)  <b>Zoom link:</b> <a href="https://who.zoom.us/j/94167083987">https://who.zoom.us/j/94167083987</a> <b>Password: AFIRM_2022</b>
	<b>Reinforcement</b> <ol style="list-style-type: none"> <li>What data is missing to allow immunobridging of filovirus vaccines? What is the fastest strategy to acquire such data?</li> <li>Is it possible to develop multivalent virus vaccines?</li> <li>How can we better accelerate the development of vaccines against Marburg and Sudan viruses?</li> <li>Is there a need to boost immunity in survivors?</li> <li>Input on WHO protocol for filovirus vaccine trials.</li> </ol>	<b>Chairs</b> Ana María Henao-Restrepo (WHO) Phil Krause (WHO)  <b>Zoom link:</b> <a href="https://who.zoom.us/j/94119183484">https://who.zoom.us/j/94119183484</a> <b>Password: AFIRM_2022</b>

	<b>Cure</b> <ol style="list-style-type: none"> <li>1. How can we better share the knowledge gained in previous outbreaks to treat filovirus patients? Is this knowledge translatable to all filovirus diseases?</li> <li>2. Which interventions improve outcome, in particular preventing multiorgan failure?</li> <li>3. What post-exposure therapies or combinations thereof are preferred? Do they have prophylactic potential as well?</li> <li>4. How can we improve collaboration in endemic countries?</li> </ol>	<b>Chairs</b> Janet Diaz (WHO) Simon Funnell (WHO, UKHSA)  <b>Zoom link:</b> <a href="https://who.zoom.us/j/91726763859">https://who.zoom.us/j/91726763859</a> <b>Password:</b> AFIRM_2022
<b>Main Room</b> <b>Zoom link:</b> <a href="https://who-e.zoom.us/meeting/register/tJUtd-GoqTMjHdSTBu1-k3ft7XfZSxXuN2i">https://who-e.zoom.us/meeting/register/tJUtd-GoqTMjHdSTBu1-k3ft7XfZSxXuN2i</a> <b>Password:</b> AFIRM		
15:30 – 16:00	Summary or breakout rooms by chairs Final Remarks and Input	
16:00	<b>END OF MEETING</b>	